Avirmax Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$3M
- Investors
-
2
Avirmax General Information
Description
Developer of gene therapy drugs intended to target chronic eye diseases. The company specializes in developing biotherapeutics using its proprietary protein therapeutics and technologies to address current challenges in viral vector productions, providing patients with effective, safe, and long-acting mediated treatment in an affordable and accessible manner.
Contact Information
Website
www.avirmax.comCorporate Office
- 25503 Whitesell Street
- Hayward, CA 94541
- United States
Corporate Office
- 25503 Whitesell Street
- Hayward, CA 94541
- United States
Avirmax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A1) | 26-Nov-2019 | $3M | Completed | Clinical Trials - General |
Avirmax Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A1 |
Avirmax Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Avirmax Patents
Avirmax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3228666-A1 | Compositions and methods for transgene expression | Pending | 23-Aug-2021 | ||
| WO-2023028004-A1 | Compositions and methods for transgene expression | Inactive | 23-Aug-2021 | ||
| CA-3210368-A1 | Compositions and methods for ocular transgene expression | Pending | 09-Apr-2021 | ||
| WO-2022217110-A1 | Compositions and methods for ocular transgene expression | Inactive | 09-Apr-2021 | ||
| WO-2022103766-A2 | Engineered viral capsids and methods of use | Inactive | 10-Nov-2020 | C12N15/86 |
Avirmax Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Avirmax Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3E Bioventures (China) | Venture Capital | Minority | ||
| Kaitai Capital | Venture Capital | Minority |
Avirmax FAQs
-
When was Avirmax founded?
Avirmax was founded in 2019.
-
Where is Avirmax headquartered?
Avirmax is headquartered in Hayward, CA.
-
What is the size of Avirmax?
Avirmax has 15 total employees.
-
What industry is Avirmax in?
Avirmax’s primary industry is Drug Discovery.
-
Is Avirmax a private or public company?
Avirmax is a Private company.
-
What is the current valuation of Avirmax?
The current valuation of Avirmax is .
-
What is Avirmax’s current revenue?
The current revenue for Avirmax is .
-
How much funding has Avirmax raised over time?
Avirmax has raised $3M.
-
Who are Avirmax’s investors?
3E Bioventures (China) and Kaitai Capital have invested in Avirmax.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
